CIM: How do you plan on competing with so many competitors in the Canadian market? Seems like the market is over-saturated and cannibalized.
Q
A
CC: As of today, there are over 200 cannabis companies trading on Canadian public exchanges. These companies are all at different stages of development and are deploying different strategies with regards to product development and business segments. Many of these are cultivators that are still awaiting approval from Health Canada or are currently constructing facilities and have yet to apply for licensing. Stigma Grow received its cultivation, processing and sales license from Health Canada in March 2019. In addition, we have 42 proprietary strains allowing for a wide variety of THC, CBD and terpene profiles, many of which containing THC as high as 30%. We believe our high-quality craft product will be attractive to consumers and we have the ability to get it to market quicker than the majority of our competitors. We feel that this, along with the advantages of our vertically-integrated structure and attention to unique, appealing brands that remain engaged with the needs of our clients, will keep us competitive in the industry long-term.
CIM: The Canadian medical marijuana market is not a large market compared to the United States, are there enough patients to support the Canadian market? Or will majority of your revenues come from recreational sales or international sales?
Q
CC: Each member of the CanadaBis management team has roughly 15-20 years of experience in their respective roles. Primarily from oil and gas backgrounds, we have met the challenges of navigating a new industry head on, each member bringing their wealth of experience and applying it to this new, every-changing space.
On the marketing and communications side, our Directors have extensive experience with both retail and LP brands, and have successfully launched and supported multiple industry leaders across Canada.
A
50